CA-based ImpriMed secures $23M in series A round funding. SBVA took the lead in the round. Additionally participating were Samyang Chemical Group, HRZ Han River Partners, SK Telecom, KDB Silicon Valley, Ignite Innovation Fund, Murex Partners, and Byucksan.
The company plans to employ more people, widen its commercial development and R&D pipeline, and expand its medication response prediction technology from veterinary medicine to human oncology with the help of the financing.
Read also – Guam-based TeleGuam Holdings Secures $200m Strategic Growth Investment
ImpriMed is a precision medicine firm utilising artificial intelligence to cure cancer. It was co-founded in 2017 by Sungwon Lim, CEO, and Jamin Koo, CTO, both eminent alumni of Stanford University and KAIST (The Korea Advanced Institute of Science and Technology).
With its drug response prediction technology, patients’ quality of life is improved, therapy is accelerated, expenses decrease, and efficacy is increased.
Read also – Ola-based Argonaut Private Equity Secures Argonaut Private Equity Fund V with $500m
As of 2023, the company’s technology was implemented in over 40 states in the United States, and over 15,000 blood cancer tests had been conducted on dogs and cats. Now, ImpriMed is prepared to broaden its AI-powered strategy to include human healthcare.
About ImpriMed
Sungwon Lim and Jamin Koo, the co-founders of ImpriMed, first connected as undergraduates and found a passion for creating cutting-edge medical technology. After completing their doctorates in engineering sciences at Stanford University, the two decided to form a startup business to address one of the biggest problems facing human disease: cancer.
Read also – Massachusetts-based Mobile Pixels Secures More Than $8m in Funding
